Vir Biotechnology (VIR) Projected to Post Quarterly Earnings on Wednesday

Vir Biotechnology (NASDAQ:VIR) is projected to issue its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.7393) per share and revenue of $0.86 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.14. The business had revenue of $238.95 million for the quarter, compared to analysts’ expectations of $135.88 million. The business’s quarterly revenue was up 19582.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.80) EPS. On average, analysts expect Vir Biotechnology to post ($1.84) EPS for the current fiscal year and ($2.61) EPS for the next fiscal year.

Vir Biotechnology Trading Up 4.8%

Shares of Vir Biotechnology stock opened at $11.57 on Wednesday. Vir Biotechnology has a 1 year low of $4.82 and a 1 year high of $12.00. The company has a market cap of $1.96 billion, a P/E ratio of -6.22 and a beta of 1.59. The stock has a 50-day moving average price of $10.81 and a 200 day moving average price of $9.40.

Wall Street Analysts Forecast Growth

VIR has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. HC Wainwright lifted their price objective on Vir Biotechnology from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. Zacks Research lowered shares of Vir Biotechnology from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 6th. Raymond James Financial restated a “strong-buy” rating on shares of Vir Biotechnology in a research note on Monday, September 28th. Finally, Morgan Stanley set a $25.00 price objective on shares of Vir Biotechnology in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $21.86.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.